AR061480A1 - 4- [2- (4-METHYLPHENYLSULPHANIL) -PENYL] PIPERIDINE AS A COMBINED INHIBITOR OF THE RECOVERY OF SEROTONIN AND NOREPINEFRINE. - Google Patents

4- [2- (4-METHYLPHENYLSULPHANIL) -PENYL] PIPERIDINE AS A COMBINED INHIBITOR OF THE RECOVERY OF SEROTONIN AND NOREPINEFRINE.

Info

Publication number
AR061480A1
AR061480A1 ARP070102640A ARP070102640A AR061480A1 AR 061480 A1 AR061480 A1 AR 061480A1 AR P070102640 A ARP070102640 A AR P070102640A AR P070102640 A ARP070102640 A AR P070102640A AR 061480 A1 AR061480 A1 AR 061480A1
Authority
AR
Argentina
Prior art keywords
piperidine
norepinefrine
methylphenylsulphanil
penyl
serotonin
Prior art date
Application number
ARP070102640A
Other languages
Spanish (es)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR061480A1 publication Critical patent/AR061480A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se proporcionan formas cristalinas de 4-[2-(4-metilfenilsulfanil)-fenil] piperidina y sales de la misma, por ej., para el tratamiento del dolor neuropático. Composiciones farmacéuticas que lo contienen y su uso para el tratamiento del dolor. Reivindicacion 1: El compuesto 1, que es 4-[2-(4-metilfenil-sulfanil)fenil]piperidina y sales aceptables para uso farmacéutico de la misma en una forma cristalina con la condicion de que dicho compuesto no sea la sal de adicion clorhidrato de 4-[2-(4-metilfenilsulfanil)fenil]-piperidina.Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine and salts thereof are provided, eg, for the treatment of neuropathic pain. Pharmaceutical compositions that contain it and its use for the treatment of pain. Claim 1: Compound 1, which is 4- [2- (4-methylphenyl-sulfanyl) phenyl] piperidine and salts acceptable for pharmaceutical use thereof in a crystalline form with the proviso that said compound is not the addition salt 4- [2- (4-methylphenylsulfanyl) phenyl] -piperidine hydrochloride.

ARP070102640A 2006-06-16 2007-06-15 4- [2- (4-METHYLPHENYLSULPHANIL) -PENYL] PIPERIDINE AS A COMBINED INHIBITOR OF THE RECOVERY OF SEROTONIN AND NOREPINEFRINE. AR061480A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600816 2006-06-16
DKPA200700423 2007-03-20

Publications (1)

Publication Number Publication Date
AR061480A1 true AR061480A1 (en) 2008-08-27

Family

ID=39722478

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102640A AR061480A1 (en) 2006-06-16 2007-06-15 4- [2- (4-METHYLPHENYLSULPHANIL) -PENYL] PIPERIDINE AS A COMBINED INHIBITOR OF THE RECOVERY OF SEROTONIN AND NOREPINEFRINE.

Country Status (15)

Country Link
JP (1) JP2014098017A (en)
KR (1) KR101472595B1 (en)
AR (1) AR061480A1 (en)
AT (1) ATE508115T1 (en)
BR (1) BRPI0712758A2 (en)
CA (1) CA2784304A1 (en)
DE (1) DE602007014372D1 (en)
DK (1) DK2044020T3 (en)
MY (1) MY150698A (en)
NZ (1) NZ572856A (en)
PT (1) PT2044020E (en)
RS (1) RS51687B (en)
SI (1) SI2044020T1 (en)
TN (1) TNSN08461A1 (en)
TW (1) TWI444365B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101972931B1 (en) 2017-10-19 2019-04-26 재단법인대구경북과학기술원 Balloon type ecog measuring device and its manufacturing method
CN116930385B (en) * 2023-08-08 2024-02-20 北京爱思益普生物科技股份有限公司 Method for measuring concentration of compound in high-salt-concentration preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (en) * 2001-10-04 2008-02-11 Х. Луннбек А/С Derivated of phenylpiperazine as serotonin reuptake inhibitorS
EP2044020B1 (en) * 2006-06-16 2011-05-04 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

Also Published As

Publication number Publication date
MY150698A (en) 2014-02-28
JP2014098017A (en) 2014-05-29
RS51687B (en) 2011-10-31
DE602007014372D1 (en) 2011-06-16
PT2044020E (en) 2011-05-12
NZ572856A (en) 2012-02-24
TW200817329A (en) 2008-04-16
TNSN08461A1 (en) 2010-04-14
DK2044020T3 (en) 2011-08-15
TWI444365B (en) 2014-07-11
KR101472595B1 (en) 2014-12-15
ATE508115T1 (en) 2011-05-15
KR20090018630A (en) 2009-02-20
SI2044020T1 (en) 2011-06-30
CA2784304A1 (en) 2007-12-21
BRPI0712758A2 (en) 2012-09-25

Similar Documents

Publication Publication Date Title
DOP2016000250A (en) AN AMORPHY FORM AND A GENZ 112638 HEMITARTRATE CRYSTALLINE AS A GLUCOSILCERAMIDE SINTASA INHIBITOR
BR112012008317A2 (en) sustained release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
PE20120083A1 (en) MONOTOSILATE SALT OF THE COMPOUND 2-METHYL-2- [4- (3-METHYL-2-OXO-8-QUINOLIN-3-IL-2, 3-DIHYDRO-IMIDAZO- [4,5-C] -QUINOLIN-1- IL) -PHENYL] -PROPIONITRILE IN ITS CRYSTALLINE FORM A
CL2011002697A1 (en) Compounds derived from 3- [4- (oxo-dihydropyridin) benzyl] -1,3-oxazin-one hydrated, 11beta-hsd1 inhibitors; pharmaceutical composition comprising them; and its use in the treatment of diabetes
CL2016002970A1 (en) Addition salts of (s) -2- (1- (6-amino-5-cyanopyrimidin-4-ylamino) ethyl) -4-oxo-3-phenyl-3,4-dihydropyrrolo [1,2-f] [ 1,2,4] triazine-5-carbonitrile.
DOP2012000150A (en) TRIAZOLOPIRIDINS
UY30136A1 (en) SPECIFIC SALT, ANHYDRA AND CRYSTALLINE FORM OF A DIHYDROPTERIDION DERIVATIVE
CO6321285A2 (en) USE OF 3,11B-CIS- DIHIDROTETRABENAZINE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND SELF-IMMUNE HONEY MIELITIS
PE20121820A1 (en) (2S, 3R) -N- (2 - ((3-PYRIDINYL) METHYL) -1-AZABICYCLE [2.2.2] OCT-3-IL) BENZOFURAN-2-CARBOXAMIDE, NOVEL SALTS FORMS OF IT, AND METHODS OF USE OF IT
PE20070800A1 (en) USE OF FLIBANSERIN FOR THE TREATMENT OF PREMENOPAUSAL SEXUAL DESIRE DISORDERS
AR065797A1 (en) USES AND DERIVATIVES OF 1- (2- (2,4- DIMETILFENILSULFANIL) PHENYL) PIPERAZINE
AR068369A1 (en) N4 XINAFOATE SALT - [(2,2-DIFLUOR-4H-BENZO [1,4] OXAZIN-3-ON) -6-IL] -5-FLUOR-N2- [3- (METHYLAMINOCARBONYLMETHYLENE) -FENYL] 2 , 4-PYRIMIDINDIAMINE "
CO6361988A2 (en) CRYSTAL FORM OF A COMPOUND OF 4- [2- (2-FLUOROPHENOXIMETHYL) PHENYL] PIPERIDINE.
PE20090742A1 (en) SOLID FORMS OF (S) -2-AMINO-3- (4- (2-AMINO-6 - ((R) -1- (4-CHLORO-2- (3-METHYL-1H-PYRAZOLE-1-IL) PHENYL) -2,2,2-TRIFLUOROETOXY) -PYRIMIDIN-4-IL) PHENYL) ETHYL PROPANOATE AND METHODS FOR ITS USE
CL2009000914A1 (en) Compounds derived from 1-cyano-3-pyrrolidinyl-n-substituted-sulfonamides, cathepsin c inhibitors; pharmaceutical composition comprising said compound; and use of the compound for the treatment of a chronic obstructive pulmonary disease.
CY1111619T1 (en) CRYSTAL FORMS 4- [2- (4-Methylphenylsulfanyl) -phenyl] piperidine with combined serotonin reuptake inhibition of serotonin N
ES2531159T3 (en) Compounds and methods for cancer treatment
AR068187A1 (en) CRYSTAL FORM OF A SYNTHETIC INTERMEDIARY FOR THE PREPARATION OF A DPP-IV INHIBITOR
CL2008000796A1 (en) USE OF 4- (2- (4-METHYLPHENYL SULFANYL) PHENYL) PIPERIDINE AND ACID ADDITION SALTS OF THE SAME FOR THE TREATMENT OF ADHD, MELANCOLIA, DEPRESSION OR RESIDUAL SYMPTOMS OF DEPRESSION; AND SUCH COMPOUND.
AR062393A1 (en) USE OF DERIVATIVE OF 2.5-DIHIDRIXIBENCENO FOR THE TREATMENT OF ARTHRITIS AND PAIN
CO2019001137A2 (en) Compound for use in the treatment of neurogenic orthostatic hypotension
CL2008001990A1 (en) Compounds derived from substituted amino-quinazolines; pharmaceutical composition comprising said compound; and use of the compound for the treatment of Alzheimer's.
AR077692A1 (en) SALTS OF 2 - ((R) - (3-CHLOROPHENYL) ((R) -1 - ((S) -2- (METHYLAMINE) -3 - ((R) -TETRAHYDRO-2H-PIRAN-3-IL) PROPILCARBAMOIL ) PIPERIDIN -3-IL) METOXI) METHYL ETILCARBAMATE
PE20091188A1 (en) COMPOUND 1- [2- (4- (3-TRIFLUOROMETIL-PHENYL) PIPERAZIN-1-IL) ETHYL] -2,3-DIHYDRO-1H-BENZIMIDAZOL-2-ONA (FLIBANSERIN), ITS ADDITION SALTS AND PHARMACEUTICAL COMPOSITIONS THAT THEY CONTAIN
CL2011000292A1 (en) Compounds derived from enfumafungin and its pharmaceutically acceptable salts, such as (1,3) -beta-d-glucan synthase inhibitors; pharmaceutical composition; and use to treat a fungal infection.

Legal Events

Date Code Title Description
FB Suspension of granting procedure